Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction

NCT05174351 | Recruiting

• 1 other identifier: 22-145-2
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.

Conditions

Heart Failure With Preserved Ejection Fraction

Keywords

HFpEF; Beta-blocker; echocardiogram; 6MWT

Outcome Measures

Primary Outcomes (1)

• Changes in KCCQ-23 score

  Kansa city cardiomyopathy questionnaire (KCCQ-23)- self-administered, 23-item. questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life. Scores are transformed to a range of 0-100, where higher scores reflect better health status.

  Baseline and after 4 weeks of beta blocker discontinuation

Secondary Outcomes (3)

• Changes in cardiac mechanics by echocardiography

  Baseline and after 4 weeks of beta blocker discontinuation

• Changes in biomarker

  Baseline and after 4 weeks of beta blocker discontinuation

• 6 minute walk test

  Baseline and after 4 weeks of beta blocker discontinuation

Study Arms (1)

HFpEF patients

EXPERIMENTAL

HFpEF patient who are currently taking beta blockers

Other: beta blocker discontinuation

Interventions

beta blocker discontinuation OTHER

beta blocker discontinuation

HFpEF patients

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100
• N=30 (Target: 30).
• Age: 50 \~ 80 years.
• ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction.
• Chronic loop diuretic use
• Currently on beta-blocker

You may not qualify if:

• Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease.
• Heart rate \> 100 bpm
• Recent hospitalization due to HF within 3 months
• Non-English speaker

Sponsors & Collaborators

• UConn Health: lead

Study Sites (1)

UConn Health / John Dempsey Hospital

Farmington, Connecticut, 06030, United States

RECRUITING

Study Officials

• Kai Chen, MD,PhD

  UConn Health

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kai Chen, MD,PhD

CONTACT

860-679-3343; kachen@uchc.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: December 2, 2021
• First Posted: December 30, 2021
• Study Start: December 20, 2021
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: September 29, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)